skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pharmaco-management of inhalation injuries for burn survivors

(2304) Views  (737) Full article downloads

Authors: Anthony C Bartley, Dale W Edgar, Fiona M Wood

Published Date January 2008 Volume 2008:2 Pages 9 - 16
DOI: http://dx.doi.org/10.2147/DDDT.S

Anthony C Bartley1, Dale W Edgar2, Fiona M Wood3

1Medical Officer, Royal Perth Hospital Burns Unit, Burns Service of Western Australia; 2McComb Clinical Researcher, Senior Physiotherapist, Burns Service of Western Australia, Curtin University of Technology; 3Director, Burns Service of Western Australia, McComb Foundation of WA, University of Western Australia, Perth, Australia

Background: Burn injury is exacerbated by inhalation injury, causing higher morbidity and mortality rates compared to those with a comparable burn injury alone. The complex pathophysiology of inhalation injury is well described, but analysis of treatment is a mammoth task and requires individual focus on a number of components of management. In this case, the focus of the review is treatment of inhalation injury using pharmacological means. It provides a concise overview of the disease process and a summary of the evidence for specific manipulation of various disease pathways.

Methods: A literature search through PubMed was completed and all links and bibliography reference articles were explored.

Results: A total of 47 papers matched the search terms. Of these, one was a comparative study with historical controls, 2 were retrospective case series, 2 studies reported a single human case series, 34 were examinations in animals, and 8 were expert opinion or reviews.

Conclusion: The literature illustrates the complicated immuno-biochemical pathways that have conflicting roles and importance, complicating integrated understanding. Secondly, there is an almost complete absence of high quality data from humans. Clinical use of pharmaco-therapies for inhalation injuries is further limited by the lack of commercial availability.

Keywords: inhalation injury, smoke, burns, inhalation, medication








Readers of this article also read:

Transdermal hormone therapy in postmenopausal women: A review of metabolic effects and drug delivery technologies
Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
New anticoagulants for the prevention of venous thromboembolism
Emerging options in growth hormone therapy: an update
Erratum
Treatment for primary hypothyroidism: current approaches and future possibilities
Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University